Gilead Sciences (GILD) Long-Term Debt Repayments (2009 - 2026)

Gilead Sciences has reported Long-Term Debt Repayments for 18 years, with the latest figure at $2.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Debt Repayments rose 56.98% year-over-year to $2.8 billion; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (down 25.19% YoY), and the FY2025 full-year result was $1.8 billion, down 9.24% from the prior year.
• Long-Term Debt Repayments for Q1 2026 stood at $2.8 billion, up from $8.0 million in the prior quarter.
• The five-year high for Long-Term Debt Repayments was $2.8 billion in Q1 2026, with the low at $7.0 million in Q4 2024.
• Historically, Long-Term Debt Repayments has averaged $934.0 million across 5 years, with a median of $500.0 million in 2022.
• Annual changes were most pronounced in 2023 — Long-Term Debt Repayments soared 125.0% — and 2025, when it sank 99.51%.
• Gilead Sciences' Long-Term Debt Repayments stood at $1.0 billion in 2022, then soared by 125.0% to $2.2 billion in 2023, then sank by 99.69% to $7.0 million in 2024, then increased by 14.29% to $8.0 million in 2025, then jumped by 34475.0% to $2.8 billion in 2026.
• The last three Long-Term Debt Repayments figures came in at $2.8 billion (Q1 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.